CLAIMS

1. A pharmaceutical composition comprising:

   a) a therapeutic compound having an anti-inflammatory activity, wherein the therapeutic compound has a log P value of greater than 2.0;

   b) a pharmaceutically-acceptable solvent, wherein the solvent comprises a pharmaceutically-acceptable polyethelene glycol polymer, a pharmaceutically-acceptable alcohol or a pharmaceutically-acceptable ester of pharmaceutically-acceptable alcohol and an acid; and

   c) at least 50% (v/v) of a pharmaceutically-acceptable hydrophobic lipid-adjuvant, wherein the pharmaceutically-acceptable hydrophobic lipid-adjuvant is a fatty acid having at least 12 carbons, a glycerolipid, a sphingolipid, a sterol lipid, a prenol lipid, a saccharolipid, or a polyketide,

   wherein the pharmaceutical composition does not comprise a pharmaceutically-acceptable emulsifying agent, and

   wherein the pharmaceutical composition is formulated to be solid at a temperature of 15°C or lower.

2. The pharmaceutical composition according to Claim 1, wherein the anti-inflammatory activity reduces the level of an inflammation inducing molecule, reduces the level of an inflammation inducing prostaglandin, stimulates a PPAR signaling pathway, induces apoptosis of Macrophage M1 cells, promotes differentiation of Macrophage M2 cells, or both, reduces the levels of Interferon- gamma (IFNy), Tumor necrosis factor-alpha (TNF-a), Interleukin-12 (IL-12), or a combination thereof released from Th1 cells, increases the levels of IL-10 released from a Th2 cell, or both.

3. The pharmaceutical composition according to Claim 1 or Claim 2, wherein the therapeutic compound comprises a non-steroidal anti-inflammatory drug (NSAID), a PPARy agonist, fibrate, and/or an ester thereof.

4. The pharmaceutical composition according to Claim 3, wherein the NSAID is a non-selective cyclo-oxygenase (COX) inhibitor, a selective cyclooxygenase 1 (COX 1) inhibitor, a selective cyclooxygenase 2 (COX 2) inhibitor or a combination thereof.

5. The pharmaceutical composition according to Claim 3, wherein the NSAID comprises a salicylate derivative NSAID, a p-amino phenol derivative NSAID, a propionic acid derivative NSAID, an acetic acid derivative NSAID, an enolic acid derivative NSAID, a fenamic acid derivative NSAID.

6. The pharmaceutical composition according to Claim 3, wherein the PPARy agonist comprises Monascin, Irbesartan, Telmisartan, mycophenolic acid, Resveratrol, Delta(9)-tetrahydrocannabinol, a cannabidiol, Curcumin, Cilostazol, Benzbromarone, 6-shogaol, glycyrrhetinic acid, a thiazolidinedione, a NSAID, a fibrate, or a combination thereof.

7. The pharmaceutical composition according to Claim 3, wherein the fibrate comprises Bezafibrate, Ciprofibrate, Clofibrate, Gemfibrozil, Fenofibrate, or a combination thereof.

~~8. The pharmaceutical composition according to any one of Claims 1-7, wherein the pharmaceutically-acceptable hydrophobic lipid-adjuvant includes at least 30% of a first glycerolipid consisting of a triglyceride or an acetylated triglyceride and at least 20% of a second glycerolipid consisting of a monoglyceride or an acetylated monoglyceride.~~

~~9.~~8. The pharmaceutical composition according to Claims 1-~~8~~7, wherein the pharmaceutically-acceptable solvent is from about 8% (v/v) to about 15% (v/v).

~~10.~~9. The pharmaceutical composition according to Claims 1-~~9~~8, wherein the pharmaceutically-acceptable solvent is from about 8% (v/v) to about 12% (v/v)

~~11.~~10. The pharmaceutical composition according to any one of Claims 1 to ~~10~~9, wherein the glycerolipid comprises a monoglyceride, a diglyceride and/or a triglyceride.

~~12. The pharmaceutical composition according to Claim 11, wherein the glycerolipid comprises at least 30% of a pharmaceutically-acceptable triglyceride and at least 20% of a~~

~~pharmaceutically- acceptable monoglyceride.~~

~~13.~~11. A method of preparing a pharmaceutical composition as defined in any one of claims 1-~~12~~10, the method comprising the steps:

a) contacting the pharmaceutically-acceptable solvent with the therapeutic compound under conditions which allow the therapeutic compound to dissolve in the pharmaceutically-acceptable solvent, thereby forming a solution, and

b) contacting the solution formed in step (a) with the pharmaceutically-acceptable hydrophobic lipid- adjuvant under conditions which allow the formation of the pharmaceutical composition.

~~14.~~12. The method according to Claim ~~13~~11, wherein step (a) further comprises contacting a pharmaceutically-acceptable stabilizing agent with the pharmaceutically-acceptable solvent and the therapeutic compound, wherein the pharmaceutically-acceptable stabilizing agent is not an emulsifying agent.

~~15.~~13. Use of a pharmaceutical composition as defined in any one of Claims 1-10~~12~~ in the manufacture of a medicament for the treatment of a chronic inflammation.

~~16.~~14. A pharmaceutical composition as defined in any one of Claims 1-~~12~~ 10 for use in the treatment of a chronic inflammation.

~~17.~~15. The use according to Claim ~~16~~14, wherein the chronic inflammation is associated with acne, acid reflux/heartburn, age related macular degeneration (AMD), allergy, allergic rhinitis, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, appendicitis, arteritis, arthritis, asthma. atherosclerosis, autoimmune disorders, balanitis, blepharitis, bronchiolitis, bronchitis, a bullous pemphigoid, burn, bursitis, cancer, cardiac arrest, carditis, celiac disease, cellulitis, cervicitis, cholangitis, cholecystitis, chorioamnionitis, chronic obstructive pulmonary disease (COPD), cirrhosis, colitis, congestive heart failure, conjunctivitis, cyclophosphamide-induced cystitis, cystic fibrosis, cystitis, common cold, dacryoadenitis, dementia, dermatitis, dermatomyositis, diabetes, diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic ulcer, digestive system disease, eczema, emphysema, encephalitis, endocarditis,

endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibromyalgia, fibrosis, fibrositis, gastritis, gastroenteritis, gingivitis, glomerulonephritis, glossitis, heart disease, heart valve dysfunction, hepatitis, hidradenitis suppurativa, Huntington's disease, hyperlipidemic pancreatitis, hypertension, ileitis, infection, inflammatory bowel disease, inflammatory cardiomegaly, inflammatory neuropathy, insulin resistance, interstitial cystitis, interstitial nephritis, iritis, ischemia, ischemic heart disease, keratitis, keratoconjunctivitis, laryngitis, lupus nephritis, mastitis, mastoiditis, meningitis, metabolic syndrome (syndrome X), a migraine, multiple sclerosis, myelitis, myocarditis, myositis, nephritis, non-alcoholic steatohepatitis, obesity, omphalitis, oophoritis, orchitis, osteochondritis, osteopenia, osteomyelitis, osteoporosis, osteitis, otitis, pancreatitis, Parkinson's disease, parotitis, pelvic inflammatory disease, pemphigus vularis, pericarditis, peritonitis, pharyngitis, phlebitis, pleuritis, pneumonitis, polycystic nephritis, proctitis, prostatitis, psoriasis, pulpitis, pyelonephritis, pylephlebitis, renal failure, reperfusion injury, retinitis, rheumatic fever, rhinitis, salpingitis, sarcoidosis, sialadenitis, sinusitis, spastic colon, stenosis, stomatitis, stroke, surgical complication, synovitis, tendonitis, tendinosis, tenosynovitis, thrombophlebitis, tonsillitis, trauma, traumatic brain injury, transplant rejection, trigonitis, tuberculosis, tumor, urethritis, ursitis, uveitis, vaginitis, vasculitis, or vulvitis.

~~18.~~16. The use according to Claim ~~16~~14, wherein the chronic inflammation is a tissue inflammation or a systemic inflammation.

~~19.~~17. The use according to Claim ~~16~~14, wherein the chronic inflammation is an auto-immune disease ~~or a non-autoimmune disease~~.

~~20.~~18. The use according to Claim ~~16~~14, wherein the chronic inflammation is associated with an arthritis, a myopathy, a vasculitis, a skin disorder, a gastrointestinal disorder, a cardiovascular disease, a cancer, a pharmacologically-induced inflammation, an infection, a tissue or organ injury, a transplant rejection, a graft-versus-host disease, a Th1-mediated inflammatory disease, a chronic neurogenic inflammation.

~~21.~~19. Use of a pharmaceutical composition as defined in any one of Claims 1-~~12~~ 10 in the manufacture of a medicament for treating a chronic inflammation, wherein the use comprises that the pharmaceutical composition is to be administered to an individual in need thereof, wherein administration results in a reduction in a symptom associated with the chronic

inflammation.

~~22.~~20. The use according to Claim ~~21~~19, wherein the chronic inflammation is associated with acne, acid reflux/heartburn, age related macular degeneration (AMD), allergy, allergic rhinitis, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, appendicitis, arteritis, arthritis, asthma. atherosclerosis, autoimmune disorders, balanitis, blepharitis, bronchiolitis, bronchitis, a bullous pemphigoid, burn, bursitis, cancer, cardiac arrest, carditis, celiac disease, cellulitis, cervicitis, cholangitis, cholecystitis, chorioamnionitis, chronic obstructive pulmonary disease (COPD), cirrhosis, colitis, congestive heart failure, conjunctivitis, cyclophosphamide-induced cystitis, cystic fibrosis, cystitis, common cold, dacryoadenitis, dementia, dermatitis, dermatomyositis, diabetes, diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic ulcer, digestive system disease, eczema, emphysema, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibromyalgia, fibrosis, fibrositis, gastritis, gastroenteritis, gingivitis, glomerulonephritis, glossitis, heart disease, heart valve dysfunction, hepatitis, hidradenitis suppurativa, Huntington's disease, hyperlipidemic pancreatitis, hypertension, ileitis, infection, inflammatory bowel disease, inflammatory cardiomegaly, inflammatory neuropathy, insulin resistance, interstitial cystitis, interstitial nephritis, iritis, ischemia, ischemic heart disease, keratitis, keratoconjunctivitis, laryngitis, lupus nephritis, mastitis, mastoiditis, meningitis, metabolic syndrome (syndrome X), a migraine, multiple sclerosis, myelitis, myocarditis, myositis, nephritis, non-alcoholic steatohepatitis, obesity, omphalitis, oophoritis, orchitis, osteochondritis, osteopenia, osteomyelitis, osteoporosis, osteitis, otitis, pancreatitis, Parkinson's disease, parotitis, pelvic inflammatory disease, pemphigus vularis, pericarditis, peritonitis, pharyngitis, phlebitis, pleuritis, pneumonitis, polycystic nephritis, proctitis, prostatitis, psoriasis, pulpitis, pyelonephritis, pylephlebitis, renal failure, reperfusion injury, retinitis, rheumatic fever, rhinitis, salpingitis, sarcoidosis, sialadenitis, sinusitis, spastic colon, stenosis, stomatitis, stroke, surgical complication, synovitis, tendonitis, tendinosis, tenosynovitis, thrombophlebitis, tonsillitis, trauma, traumatic brain injury, transplant rejection, trigonitis, tuberculosis, tumor, urethritis, ursitis, uveitis, vaginitis, vasculitis, or vulvitis.

~~23.~~21. The use according to Claim ~~21~~19, wherein the chronic inflammation is a tissue inflammation or a systemic inflammation.

~~24.~~22. The use according to Claim ~~21~~19, wherein the chronic inflammation is an auto-immune

disease ~~or a non-autoimmune disease~~.

~~25.~~23. The use according to Claim ~~21~~19, wherein the chronic inflammation is associated with an arthritis, a myopathy, a vasculitis, a skin disorder, a gastrointestinal disorder, a cardiovascular disease, a cancer, a pharmacologically-induced inflammation, an infection, a tissue or organ injury, a transplant rejection, a graft-versus-host disease, a Th1-mediated inflammatory disease, a chronic neurogenic inflammation.

~~26.~~24. The use according to Claim ~~21~~19, wherein upon administration to the individual, the pharmaceutical composition comprising the therapeutic compound results in a bio-distribution of the therapeutic compound different than a bio-distribution of the therapeutic compound included in the same pharmaceutical composition, except without the pharmaceutically-acceptable hydrophobic lipid-adjuvant.

~~27.~~25. The use according to Claim ~~21~~19, wherein upon administration to the individual, the pharmaceutical composition reduces gastric or intestinal irritation by at least 5% when compared to the pharmaceutical composition, except without the pharmaceutically-acceptable hydrophobic lipid- adjuvant.